Researchers examined the antigenicity of the emerging SARS-CoV-2 subvariant BA.2.86, finding that it is not resistant to neutralizing antibodies from previously infected or vaccinated individuals, although it does show increased binding affinity to the ACE-2 receptor. The study highlights the subvariant’s sensitivity and resistance to different classes of monoclonal antibodies, offering insights for future treatment and vaccine development.
Congressmen: This Covid hearing ‘could have been an email’
WASHINGTON — House Republicans have repeatedly accused Biden health officials of withholding and censoring documents related to pandemic policies and the origins of Covid-19. They